论文部分内容阅读
目的:探讨2型尿病和以及不同并发症患者血清护骨素(OPG)水平及调脂治疗前后其水平的比较。方法:新诊断的2型糖尿病以及合并神经病变、视网膜病变和冠心病患者各50例,另选年龄性别相匹配的50例健康者为对照组,采用ELISA法检测不同组血清OPG水平;比较辛伐他汀治疗2周后护骨素水平的变化。结果:血清同型半胱氨酸和护骨素水平在2型糖尿病及不同并发症组明显高于对照组,而且DMCVD组与DM组之间存在显著差异。调脂治疗2周后护骨素水平比较无显著差异。结论:血清护骨素在新发2型糖尿病组以及合并神经、视网膜和冠心病组患者中明显升高,与血糖控制指标相关。
Objective: To investigate the serum levels of osteoprotegerin (OPG) and its levels in patients with type 2 diabetes mellitus and different complications before and after lipid-lowering treatment. Methods: The newly diagnosed type 2 diabetes mellitus and 50 patients with neuropathy, retinopathy and coronary heart disease were selected as the control group. The serum OPG levels in different groups were detected by ELISA. Changes in the level of osteoprotegerin after 2 weeks of treatment with statin. Results: Serum levels of homocysteine and osteoprotegerin were significantly higher in type 2 diabetes mellitus and different complication groups than in control group, and there was a significant difference between DMCVD group and DM group. After two weeks of lipid-lowering treatment, the level of osteoprotegerin was no significant difference. CONCLUSION: Serum osteoprotegerin is significantly elevated in patients with newly diagnosed type 2 diabetes mellitus and in patients with neurological, retinal and coronary heart disease, and is related to the indicators of glycemic control.